Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the ... mainly as a result of the hepatitis C virus (HCV) epidemic. Previously, HCC ...

Considered once to be a lifelong disease, Hepatitis C has now been treated and cured in 1,000 patients at Kaiser Permanente.

HONOLULU (HawaiiNewsNow) - Hawaii’s Kaiser Permanente Viral Hepatitis Clinic has reached a major milestone toward combative Hepatitis outcomes. On Wednesday the clinic announced it cured its 1,000 ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Feb. 6, 2025 — The research found that heavy drinkers with either diabetes, high blood pressure or a high waist circumference are as much as 2.4 times more likely to develop advanced liver ...